ARTICLE | Finance
SillaJen slides onto KOSDAQ
Why immunotherapy play SillaJen tumbled after KOSDAQ debut
December 10, 2016 2:52 AM UTC
A combination of a large number of private shareholders and unlucky timing soured the KOSDAQ debut of SillaJen Inc. (KOSDAQ:215600), but the proceeds should finance the cancer immunotherapy company’s Phase III trial for oncolytic virus Pexa-Vec pexastimogene devacirepvec to treat first-line hepatocellular carcinoma.
On Dec. 6, SillaJen raised W150 billion ($135 million) through the sale of 10 million shares at W15,000 in its IPO, valuing the company at about W925 billion ($832.5 million). ...